m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03323)
Name
BMS 536924
Status
Preclinical
Structure
Formula
C25H26ClN5O3
InChI
1S/C25H26ClN5O3/c1-15-11-18(31-7-9-34-10-8-31)13-20-23(15)30-24(29-20)22-19(5-6-27-25(22)33)28-14-21(32)16-3-2-4-17(26)12-16/h2-6,11-13,21,32H,7-10,14H2,1H3,(H,29,30)(H2,27,28,33)/t21-/m1/s1
InChIKey
ZWVZORIKUNOTCS-OAQYLSRUSA-N
PubChem CID
135440466
TTD Drug ID
D0M4SY
VARIDT Drug ID
DR01619
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
Cyclin-dependent kinase 2 (CDK2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BMS 536924. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of BMS 536924 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [3], [4]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BMS 536924 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [4], [5]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BMS 536924 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [3], [4]
Erbb2 tyrosine kinase receptor (HER2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for BMS 536924. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of BMS 536924 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). [6], [7]
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for BMS 536924. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS 536924 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). [7], [8]
Extracellular signal-regulated kinase 2 (ERK2)
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BMS 536924. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BMS 536924 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [9], [10]
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BMS 536924. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS 536924 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [10], [11]
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BMS 536924 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). [10], [11]
Focal adhesion kinase 1 (FAK)
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Focal adhesion kinase 1 (FAK) is a therapeutic target for BMS 536924. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of BMS 536924 through regulating the expression of Focal adhesion kinase 1 (FAK). [12], [13]
G1/S-specific cyclin-E1 (CCNE1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-E1 (CCNE1) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of G1/S-specific cyclin-E1 (CCNE1). [14], [15]
Insulin-like growth factor I receptor (IGF1R)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS 536924. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS 536924 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). [16], [17]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). [17], [18]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS 536924. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BMS 536924 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). [17], [19]
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS 536924. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of BMS 536924 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). [17], [20]
Platelet-derived growth factor receptor alpha (PDGFRA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). [21], [22]
Platelet-derived growth factor receptor beta (PDGFRB)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Platelet-derived growth factor receptor beta (PDGFRB) is a therapeutic target for BMS 536924. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of BMS 536924 through regulating the expression of Platelet-derived growth factor receptor beta (PDGFRB). [23], [24]
Proto-oncogene c-Met (MET)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Met (MET) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of Proto-oncogene c-Met (MET). [25], [26]
RAC-alpha serine/threonine-protein kinase (AKT1)
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [27], [28]
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [11], [28]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [28], [29]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [28], [30]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [28], [31]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [28], [32]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [28], [33]
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [11], [28]
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). [20], [28]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Mol Cancer Ther. 2011 Jan;10(1):117-25.
Ref 3 FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1323-1330. doi: 10.1016/j.bbalip.2018.08.008. Epub 2018 Aug 13.
Ref 4 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22. doi: 10.1016/s0960-894x(02)00884-3.
Ref 5 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.
Ref 6 FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells. Clin Exp Metastasis. 2022 Aug;39(4):623-639. doi: 10.1007/s10585-022-10169-4. Epub 2022 May 7.
Ref 7 Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8. doi: 10.1016/s0960-894x(99)00185-7.
Ref 8 IGF2BP2 promotes the progression of colorectal cancer through a YAP-dependent mechanism. Cancer Sci. 2021 Oct;112(10):4087-4099. doi: 10.1111/cas.15083. Epub 2021 Aug 3.
Ref 9 hnRNPA2B1 Promotes Colon Cancer Progression via the MAPK Pathway. Front Genet. 2021 Sep 22;12:666451. doi: 10.3389/fgene.2021.666451. eCollection 2021.
Ref 10 Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. doi: 10.1021/jm0408767.
Ref 11 N6-methyladenosine reader YTH N6-methyladenosine RNA binding protein 3 or insulin like growth factor 2 mRNA binding protein 2 knockdown protects human bronchial epithelial cells from hypoxia/reoxygenation injury by inactivating p38 MAPK, AKT, ERK1/2, and NF-KappaB pathways. Bioengineered. 2022 May;13(5):11973-11986. doi: 10.1080/21655979.2021.1999550.
Ref 12 WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer. Cancer Lett. 2019 Jun 1;451:48-57. doi: 10.1016/j.canlet.2019.02.043. Epub 2019 Mar 6.
Ref 13 Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52. doi: 10.1074/jbc.M606695200. Epub 2007 Mar 28.
Ref 14 Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A-dependent manner. J Cell Mol Med. 2020 Mar;24(6):3521-3533. doi: 10.1111/jcmm.15042. Epub 2020 Feb 10.
Ref 15 Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36. doi: 10.1021/jm020319p.
Ref 16 IGF2BP2 promotes gastric cancer progression by regulating the IGF1R-RhoA-ROCK signaling pathway. Cell Signal. 2022 Jun;94:110313. doi: 10.1016/j.cellsig.2022.110313. Epub 2022 Mar 16.
Ref 17 ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol. 2007 May 7;562(1-2):1-11. doi: 10.1016/j.ejphar.2007.01.052. Epub 2007 Feb 3.
Ref 18 m(6) A modification of lncRNA PCAT6 promotes bone metastasis in prostate cancer through IGF2BP2-mediated IGF1R mRNA stabilization. Clin Transl Med. 2021 Jun;11(6):e426. doi: 10.1002/ctm2.426.
Ref 19 ALKBH5 regulates IGF1R expression to promote the Proliferation and Tumorigenicity of Endometrial Cancer. J Cancer. 2020 Jul 25;11(19):5612-5622. doi: 10.7150/jca.46097. eCollection 2020.
Ref 20 m(6)A Reader YTHDC2 Promotes Radiotherapy Resistance of Nasopharyngeal Carcinoma via Activating IGF1R/AKT/S6 Signaling Axis. Front Oncol. 2020 Jul 31;10:1166. doi: 10.3389/fonc.2020.01166. eCollection 2020.
Ref 21 METTL3-mediated N (6)-methyladenosine modification governs pericyte dysfunction during diabetes-induced retinal vascular complication. Theranostics. 2022 Jan 1;12(1):277-289. doi: 10.7150/thno.63441. eCollection 2022.
Ref 22 Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201. doi: 10.1021/jm050231m.
Ref 23 Mutant NPM1-Regulated FTO-Mediated m(6)A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis. Front Oncol. 2022 Feb 8;12:817584. doi: 10.3389/fonc.2022.817584. eCollection 2022.
Ref 24 (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J Med Chem. 2005 Dec 29;48(26):8163-73. doi: 10.1021/jm050680m.
Ref 25 RNA m(6) A methylation regulates uveal melanoma cell proliferation, migration, and invasion by targeting c-Met. J Cell Physiol. 2020 Oct;235(10):7107-7119. doi: 10.1002/jcp.29608. Epub 2020 Feb 4.
Ref 26 Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4. doi: 10.1016/j.bmcl.2009.03.110. Epub 2009 Mar 27.
Ref 27 HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells. Cancer Lett. 2021 Oct 10;518:152-168. doi: 10.1016/j.canlet.2021.07.015. Epub 2021 Jul 14.
Ref 28 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. doi: 10.1042/0264-6021:3510095.
Ref 29 METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner. Cancer Manag Res. 2020 Dec 23;12:13173-13184. doi: 10.2147/CMAR.S286275. eCollection 2020.
Ref 30 Methyltransferase-like 3 promotes the progression of lung cancer via activating PI3K/AKT/mTOR pathway. Clin Exp Pharmacol Physiol. 2022 Jul;49(7):748-758. doi: 10.1111/1440-1681.13647. Epub 2022 May 23.
Ref 31 ALKBH5-mediated m(6)A demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling. Cell Death Dis. 2021 Dec 1;12(12):1121. doi: 10.1038/s41419-021-04401-4.
Ref 32 YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition. Exp Hematol Oncol. 2021 Jun 4;10(1):35. doi: 10.1186/s40164-021-00227-0.
Ref 33 YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Mol Cancer. 2020 Oct 29;19(1):152. doi: 10.1186/s12943-020-01267-6.